Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Continuous-wave frequency upconversion with a molecular optomechanical nanocavity

  • Chen, Wen
  • Roelli, Philippe
  • Hu, Huatian
  • Verlekar, Sachin
  • Amirtharaj, Sakthi Priya
  • Barreda, Ángela I.
  • Kippenberg, Tobias J.
  • Verhagen, Ewold
  • Galland, Christophe
  • Kovylina-Zabyako, Miroslavna
  • Martínez, Alejandro|||0000-0001-5448-0140
[EN] Coherent upconversion of terahertz and mid-infrared signals into visible light opens new horizons for spectroscopy, imaging, and sensing but represents a challenge for conventional nonlinear optics. Here, we used a plasmonic nanocavity hosting a few hundred molecules to demonstrate optomechanical transduction of submicrowatt continuous-wave signals from the mid-infrared (32 terahertz) onto the visible domain at ambient conditions. The incoming field resonantly drives a collective molecular vibration, which imprints a coherent modulation on a visible pump laser and results in upconverted Raman sidebands with subnatural linewidth. Our dual-band nanocavity offers an estimated 13 orders of magnitude enhancement in upconversion efficiency per molecule. Our results demonstrate that molecular cavity optomechanics is a flexible paradigm for frequency conversion leveraging tailorable molecular and plasmonic properties., This work received funding from the European Union's Horizon 2020 Research and Innovation Program under grant agreement nos. 829067 (FET Open THOR), 820196 (ERC CoG QTONE), and 732894 (HOT). C.G. acknowledges support from the Swiss National Science Foundation (project nos. 170684 and 198898). This work is part of the research program of the Netherlands Organisation for Scientific Research (NWO). A.I.B. acknowledges financial support by the Alexander von Humboldt Foundation.
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Unravelling the Antifibrinolytic Mechanism of Action of the 1,2,3-Triazole Derivatives

  • Rabadà, Yvette
  • Bosch-Sanz, Oriol
  • Biarnés, Xevi
  • Pedreño, Javier
  • Caveda, Luis
  • Sánchez-García, David
  • Martorell López, Jordi
  • Balcells, Mercedes
A new family of antifibrinolytic drugs has been recently discovered, combining a triazole moiety, an oxadiazolone, and a terminal amine. Two of the molecules of this family have shown activity that is greater than or similar to that of tranexamic acid (TXA), the current antifibrinolytic gold standard, which has been associated with several side effects and whose use is limited in patients with renal impairment. The aim of this work was to thoroughly examine the mechanism of action of the two ideal candidates of the 1,2,3-triazole family and compare them with TXA, to identify an antifibrinolytic alternative active at lower dosages. Specifically, the antifibrinolytic activity of the two compounds (1 and 5) and TXA was assessed in fibrinolytic isolated systems and in whole blood. Results revealed that despite having an activity pathway comparable to that of TXA, both compounds showed greater activity in blood. These differences could be attributed to a more stable ligand–target binding to the pocket of plasminogen for compounds 1 and 5, as suggested by molecular dynamic simulations. This work presents further evidence of the antifibrinolytic activity of the two best candidates of the 1,2,3-triazole family and paves the way for incorporating these molecules as new antifibrinolytic therapies., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Unravelling the Antifibrinolytic Mechanism of Action of the 1,2,3-Triazole Derivatives

  • Rabadà, Yvette
  • Bosch-Sanz, Oriol
  • Biarnés, Xevi
  • Pedreño, Javier
  • Caveda, Luis
  • Sánchez-García, David
  • Martorell López, Jordi
  • Balcells, Mercedes
A new family of antifibrinolytic drugs has been recently discovered, combining a triazole moiety, an oxadiazolone, and a terminal amine. Two of the molecules of this family have shown activity that is greater than or similar to that of tranexamic acid (TXA), the current antifibrinolytic gold standard, which has been associated with several side effects and whose use is limited in patients with renal impairment. The aim of this work was to thoroughly examine the mechanism of action of the two ideal candidates of the 1,2,3-triazole family and compare them with TXA, to identify an antifibrinolytic alternative active at lower dosages. Specifically, the antifibrinolytic activity of the two compounds (1 and 5) and TXA was assessed in fibrinolytic isolated systems and in whole blood. Results revealed that despite having an activity pathway comparable to that of TXA, both compounds showed greater activity in blood. These differences could be attributed to a more stable ligand–target binding to the pocket of plasminogen for compounds 1 and 5, as suggested by molecular dynamic simulations. This work presents further evidence of the antifibrinolytic activity of the two best candidates of the 1,2,3-triazole family and paves the way for incorporating these molecules as new antifibrinolytic therapies., info:eu-repo/semantics/publishedVersion